Effects of Whole-Body Cryotherapy in Comparison with Other Physical Modalities Used with Kinesitherapy in Rheumatoid Arthritis
Table 1
Baseline characteristics of the 44 patients with rheumatoid arthritis.
Group I (): WBC group
Group II (): TR group
Age (years)
55.9 ± 5.08 (55; 51–60)
57.4 ± 5.3 (57; 52–61)
0.3373
BMI (kg/m2)
25.5 ± 2.71 (25.1; 24.1–26.8)
28.5 ± 4.78 (30.1; 23–32.9)
0.0565
DAS28
5.27 ± 1.13 (5.53; 4.15–6.18)
4.97 ± 0.87 (4.95; 4.22–5.58)
0.4409
Disease duration (years)
11 ± 5.37 (9; 8–15)
10.7 ± 9.2 (6; 3.5–18)
0.9058
RF positive, (%)
17 (68)
13 (68)
Treatment
NSAID, (%)
18 (74.1)
13 (68.4)
DMARDs, (%)
25 (100)
19 (100)
Glucocorticoids, (%)
16 (66.7)
16 (84.2)
Prednisolone (mg/day)
4 ± 0.85
3.4 ± 0.94
All data are expressed as mean ± SD (median; interquartile range) and percentages. WBC: whole-body cryotherapy; TR: traditional rehabilitation; BMI: body mass index; DAS28: Disease Activity Score 28; RF: rheumatoid factor; DMARDs: disease-modifying antirheumatic drugs.
